Trivitron Healthcare, a private equity-backed medical technology firm, is planning to start pilot production in its third manufacturing facility at the Medical Technology Park here, by the end of this year.
The 25-acre park is expected to house the facilities for various joint ventures and acquisitions of Trivitron, which would bring in the strength of manufacturing activities to the company.
“We will be starting the pilot operations in the third facility from this month or next month and the commercial productions would start from early next year. This is one of the largest facilities in medical technology, spanning around 80,000 sft, of which almost 40,000 sft is a cleanroom facility,” said GSK Velu, managing director, Trivitron.
He said the third facility would be coming up with an investment of Rs 50 crore, without considering the land cost. The company has already invested around Rs 120 crore in all the three factories in the park, while the overall project is expected to be of Rs 250 crore. The park could accommodate 10-15 facilities in the next five years, he added.
While it has completed a few acquisitions in the imaging technology space, it would now be looking at an acquisition in the critical care operations. The company would be looking at companies with Euro 10 million ticket size for acquisition.
The company, with a turnover of Rs 550 crore last year, is expecting its topline to grow to Rs 750 crore this year. It has set a goal to take the revenues to Rs 2,000 crore in three-five years.
In Dec 2013, India Value Fund Advisors picked up a minority stake in Trivitron by infusing Rs 150 crore, joining the existing investors Fidelity Growth Partners India and Fidelity Biosciences (USA) who invested in the company a year before that.
